Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC - JTO Clinical and Research Reports
Novel Entrectinib Trial Focuses on Gene Rearrangements Across Many Tumor Types
Cancers | Free Full-Text | Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers | HTML
Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours
Frontiers | Clinical Trial Eligibility Criteria and Recently Approved Cancer Therapies for Patients With Brain Metastases
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials - The Lancet Oncology
carcinoid clinical trials Archives - Carcinoid Cancer Foundation
Trial record 1 of 1 for: RXDX-101-02 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors H
STARTRK2 Clinical Trial: A Basket Study of Entrectinib for the Treatment of Solid Tumors with Specific Gene Rearrangements
Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies - ESMO Open
Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours - ESMO Open
A Design Agency + Infusing Digital Media & Creative Branding.
ALKA-372-001, STARTRK-1, and STARTRK-2 Trials
From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm: Trends in Cancer
STARTRK2 Clinical Trial: A Basket Study of Entrectinib for the Treatment of Solid Tumors with Specific Gene Rearrangements
Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population | npj Precision Oncology
Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population | npj Precision Oncology
Latest Rectal cancer Clinical Trials - Search and Apply Today
Entrectinib Is Effective Across NTRK Fusion Positive Solid Tumour Types
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials - The Lancet Oncology
EX-99.2
Healthcare Corporate Video Portfolio | DigiVid360
PDF) O-3 Efficacy and safety of entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis of three clinical trials (STARTRK-2, STARTRK-1 and ALKA-372-001)
Rx Pipeline | Precision Cancer Therapeutics | Ignyta.com
Entrectinib, a new multi-target inhibitor for cancer therapy - ScienceDirect
Pharmaceuticals | Free Full-Text | TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs | HTML
STARTRK2 Ignyta Clinical Trial! - Cactus Cancer Society
